Literature DB >> 33456348

Factors Affecting the Outcomes of Patients with Malignant Rhabdoid Tumors: A Population-Based Study.

Wen Cai1,2, Xue Liu3, Weiting Ge2, Dehao Wu2, Junxi Xu3, Rui Bai3, Hanguang Hu3.   

Abstract

Objective: Malignant rhabdoid tumor (MRT) is a rare but aggressive malignancy. It has been a long time since data on this tumor have been updated.
Methods: We retrospectively reviewed patients from the SEER database who were pathologically diagnosed with MRT and analyzed incidence rates, clinical features and survival using Stata 12.0.
Results: In total, 544 patients were included in the epidemiological analysis. There were two peak periods of MRT incidence: patients younger than 4 years and those older than 70 years. Further survival analysis showed that the survival of children (especially younger than 1 year) was markedly worse than that of adults (P<0.01), and different primary sites were associated with different age groups and survival outcomes. The central nervous system (CNS) was the most common primary site (50.00%), followed by the kidney (15.66%). Patients with MRTs that originated from the digestive system experienced worse survival outcomes than those with MRTs originating from other locations. Primary site surgery conferred survival benefits to patients with renal and digestive system MRTs (HR = 0.06, CI: 0.02-0.23, P<0.01; HR=0.10, CI: 0.02-0.48, P<0.01), whereas radiotherapy conferred benefits to patients with CNS, bone and soft tissue MRTs (HR=0.22, CI: 0.15-0.34, P<0.01; HR=0.44, CI: 0.21-0.90 P=0.03). Conclusions: Our results indicate that age and the primary site of MRT are critical clinical factors that affect patient survival and treatment choices. Primary site tumor resection should be considered for renal and digestive system MRTs, and systematic therapy, including surgery and radiotherapy, should be recommended for the treatment of CNS, bone and soft tissue MRTs. © The author(s).

Entities:  

Keywords:  Epidemiology; Malignant rhabdoid tumor; Risk factors; SEER

Year:  2021        PMID: 33456348      PMCID: PMC7807195          DOI: 10.7150/ijms.51186

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


  22 in total

Review 1.  [Congenital rhabdoid tumor in the mediastinum and liver. Case report and review of the literature].

Authors:  H Maschek; M Werner; G Büsche; P Weinel
Journal:  Pathologe       Date:  1992-05       Impact factor: 1.011

2.  Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience).

Authors:  Yi-Wei Chen; Tai-Tong Wong; Donald Ming-Tak Ho; Pin-I Huang; Kai-Ping Chang; Cheng-Ying Shiau; Sang-Hue Yen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-06       Impact factor: 7.038

3.  p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.

Authors:  Sriram Venneti; Paul Le; Daniel Martinez; Katherine W Eaton; Nikhil Shyam; Kelly L Jordan-Sciutto; Bruce Pawel; Jaclyn A Biegel; Alexander R Judkins
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

4.  Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system.

Authors:  Atmaram S Pai Panandiker; Thomas E Merchant; Chris Beltran; Shengjie Wu; Shelly Sharma; Frederick A Boop; Jesse J Jenkins; Kathleen J Helton; Karen D Wright; Alberto Broniscer; Larry E Kun; Amar Gajjar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-19       Impact factor: 7.038

5.  Radiotherapy in the multimodal treatment of extrarenal extracranial malignant rhabdoid tumors.

Authors:  Dev R Puri; Paul A Meyers; Dennis H Kraus; Michael P Laquaglia; Leonard H Wexler; Suzanne L Wolden
Journal:  Pediatr Blood Cancer       Date:  2008-01       Impact factor: 3.167

Review 6.  Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy.

Authors:  Sarah E Squire; Michael D Chan; Karen J Marcus
Journal:  J Neurooncol       Date:  2006-07-20       Impact factor: 4.130

7.  The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Hematol J       Date:  2000

8.  Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience.

Authors:  L Lafay-Cousin; C Hawkins; A S Carret; D Johnston; S Zelcer; B Wilson; N Jabado; K Scheinemann; D Eisenstat; C Fryer; A Fleming; C Mpofu; V Larouche; D Strother; E Bouffet; A Huang
Journal:  Eur J Cancer       Date:  2011-10-22       Impact factor: 9.162

9.  Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.

Authors:  Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

10.  Atypical teratoid rhabdoid tumor: current therapy and future directions.

Authors:  Kevin F Ginn; Amar Gajjar
Journal:  Front Oncol       Date:  2012-09-12       Impact factor: 6.244

View more
  1 in total

1.  Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement.

Authors:  Katherine E Miller; Gregory Wheeler; Stephanie LaHaye; Kathleen M Schieffer; Sydney Cearlock; Lakshmi Prakruthi Rao Venkata; Alejandro Otero Bravo; Olivia E Grischow; Benjamin J Kelly; Peter White; Christopher R Pierson; Daniel R Boué; Selene C Koo; Darren Klawinski; Mark A Ranalli; Ammar Shaikhouni; Ralph Salloum; Margaret Shatara; Jeffrey R Leonard; Richard K Wilson; Catherine E Cottrell; Elaine R Mardis; Daniel C Koboldt
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.